Perineal Reconstruction Following eLAPE and Simultaneous Stoma Sublay Reinforcement
PRESSUR
1 other identifier
observational
20
3 countries
3
Brief Summary
This is a prospective, multicenter, single arm, observational pilot study to assess the clinical outcomes of Strattice Reconstructive Tissue Matrix for perineal reconstruction following eLAPE and simultaneous stoma reinforcement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2013
Typical duration for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2012
CompletedFirst Posted
Study publicly available on registry
August 22, 2012
CompletedStudy Start
First participant enrolled
March 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2015
CompletedDecember 8, 2015
December 1, 2015
2.5 years
August 19, 2012
December 7, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Perineal wound healing
Perineal wound healing will be assessed using the Southamptom Wound Scoring System and perineal pain assessed using a visual analogue scale (VAS) daily during hospital stay and then POD 7, 30 and months 3, 6 and 12.
12 months
Secondary Outcomes (2)
Incidence of perineal herniation
24 months
Incidence of parastomal hernia
24 months
Study Arms (1)
Strattice
eLAPE
Interventions
Eligibility Criteria
patients with low rectal carcinoma
You may qualify if:
- Primary cancers undergoing curative surgery (R0)
- Life expectancy \> 2 yrs
- Neoadjuvant radiotherapy with or without chemotherapy
You may not qualify if:
- Pelvic extenteration or extended resections
- Previously irradiated patients (i.e. radiation therapy for a previous cancer)
- Co-morbidities of: systemic infection, chronic liver failure, chronic renal failure, HIV, Hepatitis C, other advanced/metastatic cancer, collagen disorder
- sensitivity to porcine derived products or polysorbate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospitals, Leicesterlead
- Karolinska University Hospitalcollaborator
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)collaborator
- Slagelse Hospitalcollaborator
Study Sites (3)
Slagelse Hospital
Slagelse, Denmark
Karolinska University Hospital
Stockholm, Sweden
University Hospitals Leicester
Leicester, LE5 4PW, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Baljit Singh, FRCS, FACS
University Hospital Leicester, UK
- PRINCIPAL INVESTIGATOR
Sanjay Chaudhri, FRCS
University Hospital Leicester, UK
- PRINCIPAL INVESTIGATOR
Per J Nilsson, MD
Karolinska Institutet
- PRINCIPAL INVESTIGATOR
Pierre J Maina, MD
Slagelse Hospital, Denmark
- PRINCIPAL INVESTIGATOR
W Bemelman, MD
Academic Medical Center, Amsterdam, Netherlands
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2012
First Posted
August 22, 2012
Study Start
March 1, 2013
Primary Completion
September 1, 2015
Study Completion
September 1, 2015
Last Updated
December 8, 2015
Record last verified: 2015-12